Compare BioNano Genomics Inc (BNGO) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $72.71. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | VEA | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | — |
52-Week High | $4.92 | $72.89 |
52-Week Low | $1.06 | $58.19 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
VEA trades at $73.22, up 0.99% with a bullish technical outlook supported by moving averages. The ETF provides diversified exposure to developed international markets excluding the U.S. Recent institutional activity shows mixed sentiment with both new positions and reductions. VEA's low expense ratio of 0.03% and competitive dividend yield remain key advantages for international diversification.
Outlook remains positive for long-term investors seeking international exposure, though near-term technical indicators show potential overbought conditions. Key risks include currency fluctuations and global economic uncertainty. The ETF's cost efficiency and broad diversification support its appeal despite mixed institutional positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
